(Q88106792)
Statements
Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry (English)
Heinrike Schmeling
Kirsten Minden
Ivan Foeldvari
Gerd Ganser
Tony Hospach